Semaglutide denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Semaglutide on Medical-Necessity Grounds

Semaglutide is prescribed for type 2 diabetes and, in its higher-dose formulation, for chronic weight management. Aetna's medical-necessity denials for semaglutide most commonly arise when submitted documentation does not clearly establish that the patient meets Aetna's coverage criteria — for example, incomplete documentation of diagnosis, insufficient evidence of prior therapy trials, or the absence of clinical severity markers that Aetna's policy requires. For weight management specifically, denials frequently occur when structured lifestyle intervention history is not documented in the chart.

## Why This Denial Is Appealable

Medical necessity is a judgment call, and Aetna's internal reviewer may not have had access to the full clinical picture. Your prescriber's determination that semaglutide is medically necessary carries significant weight, particularly when supported by comprehensive chart documentation. Many medical-necessity denials are overturned at internal appeal or external review when complete records are submitted.

## Your Federal Appeal Rights

• Internal appeal: You must exhaust internal appeal before external review. Aetna must provide a written explanation of which medical-necessity criteria were not met. Your appeal should directly address each criterion.
• ACA §2719 / External Review: After an adverse internal decision, independent external review is available. You generally have approximately four months from the denial notice. External reviewers apply accepted medical evidence standards independently of Aetna's policy.
• ERISA §503 (employer plans): Guarantees a full-and-fair review, the complete claim file, and written criteria disclosure.
• Expedited review: Available when standard timelines would seriously jeopardize your health.

## Appeal Timeline

1. Request the denial letter and the specific Aetna medical policy invoked — both must be provided. 2. Work with your prescriber to compile documentation addressing every unmet criterion. 3. File the internal appeal within the deadline stated in the denial letter. 4. If upheld internally, request external review immediately — track the four-month window.

## Documentation to Gather

• Diagnosis confirmation: Physician records and relevant laboratory results confirming the diagnosis for which semaglutide is prescribed (diabetes or obesity/overweight with related condition).
• Prior therapy history: For diabetes: documentation of prior agents trialed, dates, outcomes, and reasons for advancement. For weight management: documented history of structured lifestyle intervention, including program type, duration, and outcomes.
• Clinical severity: Current HbA1c or weight-related clinical data from the chart; comorbidity documentation where applicable.
• Prescriber medical-necessity letter: A detailed letter from the prescribing clinician addressing each criterion in Aetna's medical policy, citing specific chart facts for each.
• Guideline support: A reference to the applicable professional society guideline (without citing specific numbers) supporting the prescribed use for this patient's diagnosis.

## Criteria-Mapping Structure

Obtain Aetna's medical policy for semaglutide (available on Aetna's provider portal or upon request). Create a table with each policy requirement in the left column and the corresponding chart-documented fact in the right column. The prescriber's letter should address each row explicitly. This structure prevents the reviewer from issuing a vague denial and forces a criterion-by-criterion evaluation.